
Photo taken from ESMO/LinkedIn
Jul 22, 2024, 11:36
Breaking Science in Gastrointestinal Cancers with Michel P. Ducreux – ESMO
ESMO shared on LinkedIn:
“For ESMO members: Breaking Science in Gastrointestinal Cancers.
Michel P. Ducreux presents his findings on Sequences of regorafenib and trifluridine/tipiracil after failure of standard therapies for mCRC.
Explore this video and the entire series on OncologyPRO now.”
Source: ESMO/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 13, 2025, 10:43
Mar 13, 2025, 10:14
Mar 13, 2025, 10:06
Mar 13, 2025, 09:32
Mar 13, 2025, 09:10
Mar 13, 2025, 09:07
Mar 13, 2025, 08:55
Mar 13, 2025, 08:44